Luminary Learning Gastrointestinal Disorder- Issue 1

26  • LUMINARY LEARNING: GASTROINTESTINAL DISORDERS 6. JiangC, XuQ,WenX, SunH (2015) Current developments inpharmacological therapeutics for chronic constipation. Acta Pharm Sin B 5:300–309. 7. Lacy BE, Chey WD, Lembo AJ (2015) New and Emerging treatment options for irritable bowel syndrome. Gastroenterol Hepatol (NY) 11:1–19. 8. Jarmuz A, Zielinska M, Storr M, Fichna J (2015) Emerging treatments in neurogastroenterology: perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases. Neurogastroenterol Motil 27:1057–1068. 9. Maneerattanaporn M, Chang L, Chey WD (2011) Emerging pharmacological therapies for the irritable bowel syndrome. Gastroenterol Clin North Am 40:223–243. 10. Birbe R, Palazzo JP, Walters R, Weinberg D et al (2005) Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum Pathol 36:170–179. 11. Lima AA, Fonteles MC (2014) From Escherichia coli heat-stable enterotoxin to mammalian endogenous guanylin hormones. Braz J Med Biol Res 47:179–191. 12. Steinbrecher KA, Cohen MB (2011) Transmembrane guanylate cyclase in intestinal pathophysiology. Curr Opin Gastroenterol 27:139–145. 13. Busby RW, Bryant AP, Bartolini WP, Cordero EA et al (2010) Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol 649:328–335. 14. Busby RW, Kessler MM, BartoliniWP, Bryant AP et al (2013) Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther 344:196–206. 15. Sheppard DN, Welsh MJ (1999) Structure and function of the CFTR chloride channel. Physiol Rev 79:S23–S45. 16. StrongTV, Boehm K, Collins FS (1994) Localization of cystic fibrosis transmembrane conductance regulator mRNA in the human gastrointestinal tract by in situ hybridization. J Clin Invest 93:347–354. 17. de Lisle RC, Meldi L, Roach E, Flynn M et al (2009) Mast cells and gastrointestinal dysmotility in the cystic fibrosis mouse. PLoS ONE 4:e4283. 18. Bodewes FA, Verkade HJ, Taminiau JA, Borowitz D et al (2015) Cystic fibrosis and the role of gastrointestinal outcome measures in the new era of therapeutic CFTR modulation. J Cyst Fibros 14:169–177. 19. Lynch SV, Goldfarb KC, Wild YK, Kong W et al (2013) Cystic fibrosis transmembrane conductance regulator knockout mice exhibit aberrant gastrointestinal microbiota. Gut Microbes 4:41–47. 20. Salaga M, Sobczak M, Fichna J (2013) Inhibition of proteases as a novel therapeutic strategy in the treatment of metabolic, inflammatory and functional diseases of the gastrointestinal tract. Drug Discov Today 18:708–715. 21. Mosinska P, Zielinska M, Fichna J (2016) Expression and physiology of opioid receptors in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes 23:3–10. 22. Sobczak M, Salaga M, Storr MA, Fichna J. (2013) Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. J Gastroenterol 49:24–45. 23. Fichna J, Dicay M, Lewellyn K, Janecka A et al (2012) Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors. Inflamm Bowel Dis 18:1137–1145. 24. Salaga M, Polepally PR, Zakrzewski PK, Cygankiewicz A et al (2014) Novel orally available salvinorin A analog PR-38 protects against experimental colitis and reduces abdominal pain in mice by interaction with opioid and cannabinoid receptors. Biochem Pharmacol 92:618–626. 25. SalagaM, Polepally PR, SobczakM, Grzywacz D et al (2014) Novel orally available salvinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome. J Pharmacol Exp Ther 350:69–78. 26. Bokic T, Storr M, Schicho R (2015) Potential causes and present pharmacotherapy of irritable bowel syndrome: an overview. Pharmacology 96:76–85. 27. Chang L, Ameen VZ, Dukes GE, McSorley DJ et al (2005) A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 100:115–123. 28. Krause R, Ameen V, Gordon SH, West M et al (2007) A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol 102:1709–1719. 29. Tong K, Nicandro JP, Shringarpure R, Chuang E et al (2013) A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. Therap Adv Gastroenterol 6:344–357. 30. Chiba T, Yamamoto K, Sato S, Suzuki K (2013) Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome. Clin Exp Gastroenterol 6:123–128.